PMID- 30259578
OWN - NLM
STAT- MEDLINE
DCOM- 20190311
LR  - 20210109
IS  - 1098-2825 (Electronic)
IS  - 0887-8013 (Print)
IS  - 0887-8013 (Linking)
VI  - 33
IP  - 2
DP  - 2019 Feb
TI  - Elevation of serum oxLDL/beta2-GPI complexes was correlated with diabetic 
      microvascular complications in Type 2 diabetes mellitus patients.
PG  - e22676
LID - 10.1002/jcla.22676 [doi]
LID - e22676
AB  - BACKGROUND: High levels of oxLDL/beta2-GPI complexes might be a consequence of LDL 
      atherogenic modification mediated by oxidative stress. We aimed to determine 
      whether the levels of serum oxLDL/beta2-GPI complexes were correlated with diabetic 
      microvascular complications in type 2 diabetes mellitus (T2DM) patients. METHODS: 
      Levels of oxLDL/beta2-GPI complexes, oxLDL, routine lipid/lipoprotein parameters 
      were measured in 100 healthy controls, 128 T2DM patients without any 
      microvascular complications, and 172 T2DM patients with microvascular 
      complications. Spearman's correlation, multivariable linear regression logistic 
      regression analysis, and receiver operating characteristic (ROC) curve were 
      performed. RESULTS: Levels of serum oxLDL/beta2-GPI complexes and oxLDL were 
      significantly higher in T2DM patients with microvascular complications 
      (oxLDL/beta2-GPI complexes: 1.10 +/- 0.18 U/mL; oxLDL: 48.12 +/- 7.24 mmol/L) than those 
      in T2DM patients without microvascular complications (oxLDL/beta2-GPI complexes: 
      0.98 +/- 0.16 U/mL; oxLDL: 41.45 +/- 6.81 mmol/L) and controls (oxLDL/beta2-GPI 
      complexes: 0.79 +/- 0.15 U/mL; oxLDL: 27.85 +/- 5.32 mmol/L). Variables that remained 
      significantly associated with oxLDL/beta2-GPI complexes were oxLDL (beta = 0.568, P < 
      0.001), TC (beta = 0.312, P = 0.013) and microvascular complications (beta = 0.205, P = 
      0.027), which accounted for 58.3% of the variation of the level of oxLDL/beta2-GPI 
      complexes in T2DM patients (R(2) = 0.583). Logistic regression analysis 
      demonstrated that elevation of oxLDL/beta2-GPI complexes (OR = 3.14, 95% CI: 
      1.04-9.46, P = 0.042) and oxLDL levels (OR = 3.02, 95% CI: 1.16-7.83, P = 0.023) 
      were independently associated with occurrence of microvascular complications. 
      Cutoff value of oxLDL/beta2-GPI for the presence of microvascular complications was 
      1.05 U/mL, and AUC area of ROC curve was 0.783 (95%CI: 0.713-0.853), yielding a 
      sensitivity of 86.8% and specificity of 64.9%. CONCLUSIONS: Elevation of serum 
      oxLDL/beta2-GPI complexes was associated with microvascular complications in T2DM 
      patients.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Xie, Lianzhi
AU  - Xie L
AUID- ORCID: 0000-0001-9349-6022
AD  - Laboratory Department, The First Affiliated Hospital of Xiamen University, 
      Xiamen, China.
FAU - Lin, Hui
AU  - Lin H
AD  - Laboratory Department, The First Affiliated Hospital of Xiamen University, 
      Xiamen, China.
FAU - Wang, Caihong
AU  - Wang C
AD  - Endocrinology Department, The First Affiliated Hospital of Xiamen University, 
      Xiamen, China.
LA  - eng
PT  - Journal Article
DEP - 20180926
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Multiprotein Complexes)
RN  - 0 (beta 2-Glycoprotein I)
RN  - 0 (oxidized low density lipoprotein)
SB  - IM
MH  - Case-Control Studies
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - *Diabetic Angiopathies/blood/epidemiology
MH  - Female
MH  - Humans
MH  - Lipoproteins, LDL/*blood/chemistry/metabolism
MH  - Male
MH  - Microvessels/*physiopathology
MH  - Middle Aged
MH  - Multiprotein Complexes/blood/chemistry/metabolism
MH  - ROC Curve
MH  - beta 2-Glycoprotein I/*blood/chemistry/metabolism
PMC - PMC6818577
OTO - NOTNLM
OT  - microvascular complications
OT  - oxLDL/beta2-GPI complexes
OT  - type 2 diabetes mellitus
EDAT- 2018/09/28 06:00
MHDA- 2019/03/12 06:00
PMCR- 2018/09/26
CRDT- 2018/09/28 06:00
PHST- 2018/07/06 00:00 [received]
PHST- 2018/08/16 00:00 [revised]
PHST- 2018/08/20 00:00 [accepted]
PHST- 2018/09/28 06:00 [pubmed]
PHST- 2019/03/12 06:00 [medline]
PHST- 2018/09/28 06:00 [entrez]
PHST- 2018/09/26 00:00 [pmc-release]
AID - JCLA22676 [pii]
AID - 10.1002/jcla.22676 [doi]
PST - ppublish
SO  - J Clin Lab Anal. 2019 Feb;33(2):e22676. doi: 10.1002/jcla.22676. Epub 2018 Sep 
      26.